News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

TargeGen, Inc. Affiliates Scheduled for Oral Presentation of Interim Clinical Trial Data at 2008 American Society of Hematology Meeting in San Francisco for TG101348, a Potent, Selective, Oral JAK2 Inhibitor in Myeloproliferative Disease Patients


12/2/2008 8:50:24 AM

SAN DIEGO, Dec. 1 /PRNewswire/ -- TargeGen has announced that an oral presentation of preliminary results from a multi-center, US-based clinical trial of TG101348 in myeloproliferative disease patients has been scheduled at the 2008 American Society of Hematology (ASH) Meeting.

About TargeGen, Inc.

TargeGen, Inc. is a privately held vascular biology-focused biopharmaceutical company based in San Diego, CA. TargeGen primarily develops small molecule kinase inhibitors that target vascular leakage (edema), vascular proliferation (angiogenesis) and inflammation. Edema, angiogenesis and inflammation are involved in the pathology of many major human diseases. TargeGen initiated operations in 2002 and has raised capital from top tier venture capital sources. Current investors include VantagePoint Venture Partners, Forward Ventures, Enterprise Partners, Chicago Growth Partners, BB BIOTECH VENTURES, Innovis Investments, H&Q Capital Management, Pappas Ventures, CTI Life Sciences and other investors.

(Logo: http://www.newscom.com/cgi-bin/prnh/20030430/TARGEGENLOGO)



CONTACT: TargeGen, Inc., +1-858-678-0760, fax, +1-858-678-0160,
info@targegen.com

Web site: http://www.targegen.com/


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES